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SUMMARY
Background: This study aimed to evaluate the use of QT intervals, their diagnos-
tic predictive value in patients with syncope and their relationship with syncope
severity. Methods: One hundred and forty nine patients with a diagnosis of syn-
cope were admitted to Internal Medicine departments at the University of Palermo,
Italy, between 2006 and 2012, and 140 control subjects hospitalised for other
causes were enrolled. QT maximum, QT minimum, QTpeak, QT corrected, QT dis-
persion and Tpeak-to-Tend interval were compared between two groups. The
paper medical records were used for scoring with San Francisco Syncope Rule
(SFSR), Evaluation of Guidelines in SYncope Study (EGSYS) score and Osservatorio
Epidemiologico sulla Sincope nel Lazio (OESIL) risk score. Results: Mean QTc
(p < 0.0005), mean QTmax (p < 0.0005), mean QTdisp (p < 0.0005), mean
QTpeak (p = 0.005) and mean TpTe (p = 0.018) were significantly longer in
patients with syncope compared with control subjects. A QTc > 424.8 ms (sensi-
bility: 81.88 – specificity: 57.86) showed the greatest predictive value for diagnosis
of syncope. On the EGSYS score and on the OESIL score, QTc was significantly
prolonged in high-risk patients compared with low-risk patients. On the San Fran-
cisco Syncope Rule, QTc and QTdisp were significantly prolonged in high-risk
patients compared with low-risk patients. Conclusion: Mean QTc, mean QTdisp,
mean TpTe, mean QTmax and mean QTpeak were significantly longer in patients
with syncope compared with control subjects. Furthermore, prolonged QTc and
QTdisp were associated with major severe syncope according to San Francisco Syn-
cope Rule, EGSYS and OESIL risk scores.
What’s known
A study found that a QTc  500 msec was a
predictor of increased mortality in emergency
department patients with syncope. An increased
QTdisp is found in various cardiac diseases in several
studies and it is associated with a major risk of
torsades de pointes tachycardia. A prolonged TpTe
interval is associated with increased risk of mortality
in long-QT syndromes, in hypertrophic
cardiomyopathy and in coronary artery diseases.
What’s new
In our study, mean QTc, mean QTdisp, mean TpTe,
mean QTmax, and mean QTpeak were significantly
longer in patients with syncope compared to control
subjects. Furthermore, prolonged QTc and QTdisp
were associated to major severe syncope according
to San Francisco Syncope Rule, EGSYS and OESIL risk
scores.
Introduction
Although syncope is usually considered a benign
symptom, it is occasionally associated with signifi-
cant morbidity and mortality, which seems to be
related to the severity of the underlying disease
rather than to syncope per se (1,2). Some risk scores
evaluated the prognosis of patients affected by syn-
cope; they are the San Francisco Syncope Rule
(SFSR) (3), the EGSYS (Evaluation of Guidelines in
SYncope Study) score (4) and the OESIL (Osservato-
rio Epidemiologico sulla Sincope nel Lazio) risk
score (5). Generally, in patients with syncope, the
major risk factors for sudden cardiac death and over-
all mortality are: structural heart disease (4–7) and
primary electrical disease (8,9). Structural heart dis-
ease is a very common predisposing condition for
QT corrected (QTc) prolongation (10–12); a long
QTc interval on the surface electrocardiogram (ECG)
is often associated with precipitation of torsade de
pointes, a polymorphic ventricular tachycardia that
may cause syncope, ventricular fibrillation and sud-
den death not infrequently (1,11).
In order to understand accurately the link between
the dispersion of ventricular recovery times, arrhyth-
mias, heart diseases and mortality, in recent years
new measurements of QT intervals have been pro-
posed and used. These are the QT dispersion
(QTdisp), an index of the spatial dispersion of the
ventricular recovery times (13) and the Tpeak-to-
Tend (TpTe) interval, that is a measure of transmu-
ral dispersion of repolarisation in the left ventricle
(14).
Despite the availability of advanced diagnostic
tests, a significant proportion of patients with syn-
cope remain often misdiagnosed and undiagnosed
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especially for the periodic and unpredictable nature
of events (15,16).
In our study, we used QT intervals in order to
evaluate their predictive value in hospitalised patients
towards syncope diagnosis and their relationship
with syncope severity.
Materials and methods
The patients enrolled in our study had a diagnosis of
syncope and were admitted to the Operating Units
of ‘Circulatory Physiopathology’, ‘Vascular Medicine’
and ‘Internal Medicine and Cardioangiology’ at the
University of Palermo, Italy, between January 2006
and June 2012. Anamnesis, laboratory data and
demographic, clinical and therapeutic characteristics
were collected by reviewing the paper medical
records. Syncope was defined as a T-LOC because of
transient global cerebral hypoperfusion, characterised
by rapid onset, short duration and complete sponta-
neous recovery (1). Every non-syncope loss of con-
sciousness such as seizure, vertigo, hypoglycaemia,
dizziness, head trauma, coma, shock, cataplexy, drop
attacks and other states of altered mental status were
excluded. The control subjects were patients hospita-
lised for other causes, in the same period, at the
same Operating Units.
On the basis of anamnesis and clinical data, syn-
cope was classified in five groups: reflex (in response
to a trigger), orthostatic (secondary to an abnormal
decrease in systolic blood pressure upon standing),
cardiac or cardiovascular (secondary to arrhythmias
or structural cardiovascular diseases), multifactor (if
more causes were involved) and unexplained (unmis-
takable cause).
The ECG, anamnesis, clinical and laboratory data
were used for scoring with SFSR, EGSYS score and
OESIL risk score. According to the SFSR (3), high-
risk patients are those having at least one of the fol-
lowing risk factors: a history of congestive heart
failure, haematocrit lower than 30%, abnormal
ECG, a complaint of shortness of breath and sys-
tolic blood pressure values lower than 90 mm Hg.
The point score of EGSYS (4) is found as the sum
of the following risk factors: palpitations 4, abnor-
mal ECG/Cardiopathy 3, effort syncope 3, syncope
in supine position 2, neurovegetative prodromes
1, precipitating and predisposing factors 1. A
score greater than 2 implies an increased risk of
cardiac syncope. According to the OESIL risk score
(5), subjects with at least two of these risk factors
were assumed to be at intermediate or high risk:
abnormal ECG, a previous history of cardiovascular
diseases, absence of prodromal symptoms and age
over 65 years.
All 12-lead ECGs were performed at 25 mm/s
paper speed and 10 mm/mV amplitude. QT intervals
were measured manually on all possible leads by
three clinicians blinded to all clinical details in an
independent manner. QT interval was defined as the
interval from the onset of the QRS complex to the
end of the T wave, which was defined as its return to
the T-P baseline. If U wave was present, the QT
interval was measured to the nadir of the curve
between the T and U waves. If the T-wave amplitude
was < 1.5 mm in a particular lead, that lead was
excluded from the analysis. No subject had less than
nine measurable leads. QT minimum (QTmin) and
QT maximum (QTmax) were defined, respectively,
as the minimum and the maximum QT interval
measured in all 12 leads. QTpeak was defined as the
interval from the onset of the QRS complex to the
apex of T wave on the lead where the QTmax was
measured. Measurements of QTmin, QTmax and
QTpeak intervals were done in three consecutive car-
diac cycles and average values were obtained. QTdisp
was defined as the difference between QTmax and
QTmin. TpTe was defined as the difference between
QTmax and QTpeak. QTc was the QTmax corrected
with the Bazett formula to compensate for its known
dependence on heart rate: QTc = QT/√RR. QTdisp
was not corrected for heart rate because its depen-
dence on heart rate has never been demonstrated
(13).
Statistical analysis
Statistical analysis of quantitative and qualitative
data, including descriptive statistics, was performed
for all items. Continuous data are expressed as
mean  SD, unless otherwise specified. Baseline dif-
ferences between groups were assessed by the v2 test
or Fisher’s exact test, as needed for categorical vari-
ables, and by the independent Student t-test for con-
tinuous parameters. The univariate analysis of
variance (ANOVA) was performed for parametric vari-
ables, and post hoc analysis with the Bonferroni test
was used to determine whether there were pair-wise
differences. Linear regression analysis examined the
correlation between patient characteristics (indepen-
dent variables) and QT measurements (dependent
variable) in simple and multiple regression models.
Regression coefficients (B) and their 95% confidence
intervals (CIs) were adjusted for sex, previous stroke,
coronary artery disease (CAD), diabetes mellitus and
beta-blocker use. To assess the predictive role
towards syncope diagnosis of different cut-off values
of QT measurements, a receiver operating character-
istic (ROC) curve with calculations of area under the
curve and 95% CIs was constructed and sensitivity
and specificity values were calculated.
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Data were analysed by the Epi Info software
(version 6.0, Center for Disease Control and Preven-
tion, Atlanta, GA) and Spss Software (version 14.0,
SPSS Inc, Chicago, IL). All p-values were two-sided
and p-values less than 0.05 were considered statisti-
cally significant.
Results
We selected 179 consecutive patients admitted to the
Operating Units of ‘Circulatory Physiopathology’,
‘Vascular Medicine’ and ‘Internal Medicine and Car-
dioangiology’ between January 2006 and June 2012.
Six patients were excluded because of missing data
or poor quality ECG. Patients with atrial fibrillation
(n = 13), bundle branch block (n = 3) and implant-
able devices (n = 8) were also excluded. Medical
records of the remaining 149 patients were further
reviewed to extract data. Twenty-eight patients had
reflex syncope (18.79%), 23 orthostatic syncope
(15.44%), 13 cardiac syncope (8.72%), 14 multifactor
syncope (9.40%) and 71 unexplained syncope
(47.65%). Demographic, clinical and therapeutic
characteristics of cases and controls are presented in
Table 1. In patients with syncope, there were more
subjects of the female sex, with diabetes mellitus and
previous stroke; in controls, in contrast, there were
more subjects taking beta-blockers and with CAD.
On the SFSR, 67 patients obtained score 0
(44.97%), 57 had score 1 (38.26%), 22 score 2
(14.77%) and three score 3 (2.01%); no patients had
score 4 or 5; so there were 82 (55.03%) high-risk
patients. On the EGSYS score, 23 patients had score
1 (15.44%), 37 had score 0 (24.83%), one patient
score 1 (0.67%), 18 patients score 2 (12.08%), 66
score 3 (44.30%), one patient score 5 (0.67%), two
patients score 6 (1.34%) and one patient score 7
(0.67%), no patients had score 2, 4 or > 7. So on
EGSYS, there were 70 patients (46.98%) with an
increased risk of cardiac syncope. On OESIL risk
score, 31 patients had score 0 (20.81%), 39 had score
1 (26.17%), 30 score 2 (20.13%), 30 score 3
(20.13%) and 19 score 4 (12.75%); so there were 79
(53.02%) patients with intermediate or high risk.
Mean QTmax, mean QTmin, mean QTpeak, mean
QTc, mean QTdisp and mean TpTe were signifi-
cantly longer in patients with syncope compared
with control subjects at univariate ANOVA analysis;
these variables, except QTmin, were prolonged in
patients with syncope even after adjustment for sex,
diabetes mellitus, CAD, previous stroke and beta-
blockers (see Table 2).
According to the SFSR, patients with score 1 and
2 had longer mean QTc compared with patients with
score 0 and patients with score 1 had longer mean
QTdisp compared with patients with score 0. On the
EGSYS score, patients with score 3 had longer mean
QTc compared with patients with score 0. On the
OESIL score, patients with score 2 and 3 had longer
mean QTc than the patients with score 0.
Concerning the demographic, clinical and thera-
peutic variables analysed on multivariable logistic
regression model, CAD was significantly associated
with longer mean QTmax, mean QTpeak, mean
QTmin (see Table 3) and mean QTdisp (see
Table 4), and beta-blockers were associated with
shorter mean QTdisp and mean TpTe (see Table 4).
In order to evaluate the diagnostic power of QT
measurements in the syncope setting, we assessed the
predictive role of different cut-off values for syncope
diagnosis at ROC curve analysis: QTc > 424.8 ms
(sensibility: 81.88 – specificity: 57.86), QTdisp
>50 ms (sensibility: 48.99 – specificity: 81.43),
QTmax > 410 ms (sensibility: 46.31 – specificity:
83.57), TpTe >100 ms (sensibility: 31.54 – specificity:
89.29) and QTpeak > 330 ms (sensibility: 30.87 –
specificity: 82.86), which showed a significant predic-
tive value with an area under the ROC curve of
74.7%, 70.8%, 65.4%, 59.6% and 59.2%, respectively
(see Figure 1).
Discussion
To the best of our knowledge, this is the first study
that evaluates the diagnostic power of QT intervals
in patients with syncope. In our study, mean QTc,
mean QTdisp, mean TpTe, mean QTmax and mean
Table 1 Demographic, pathological and therapeutic
characteristics of cases and controls
Variables Cases Controls p*
Patients 149 140
Age (SD) 67 (17) 65.9 (18) 0.593†
Sex (male/female) 56/93 99/41 < 0.0005
Arterial hypertension (%) 109 (73.2) 93 (66.4) 0.213
Diabetes mellitus 58 (38.9) 25 (17.9) < 0.0005
Coronary artery disease 33 (22.1) 53 (37.9) 0.004
Previous stroke 15 (10.1) 3 (2.1) 0.005
Chronic kidney disease 7 (4.7) 2 (1.4) 0.110
Chronic obstructive
pulmonary disease
4 (2.7) 8 (5.7) 0.197
Beta-blockers 25 (16.8) 57 (40.7) < 0.0005
Antiarrhythmics
(Ic and III classes)
5 (3.4) 2 (1.4) 0.448
Psycholeptics 7 (4.7) 5 (3.6) 0.631
SD, standard deviation. *Pearson’s v2 test or Fisher’s exact
test, as needed; †Independent student t-test.
Statistically significant (p < 0.05) is shown in bold.
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QTpeak were significantly longer in patients with
syncope compared with control subjects. Among
these variables, a QTc >424.8 ms showed the greatest
predictive value for diagnosis of syncope.
Among the demographic, clinical and therapeutic
variables analysed at multivariable logistic regression
model, CAD was associated with prolonged mean
QTmax, mean QTpeak, mean QTmin and mean
QTdisp.
A study of Aggarwal et al. (17) showed a link
between CAD and prolonged QTc in patients with
syncope. In our study, a link between CAD and pro-
longed QTc was not found even though the patients
with CAD had a prolonged mean QTmax. This dis-
cordance was probably because of the fact that the
patients with CAD took more beta-blockers than
non-ischaemic subjects and consequently had lower
heart rate. Therefore, after QTmax corrected for
heart rate, QTc was not significantly different in is-
chaemic and non-ischaemic patients. Although some
authors did not find significant differences between
patients with chronic CAD and normal subjects
Table 2 QT measurements and heart rate (mean values  SD)
Measurements Cases Controls p* p†
QTmax (ms) 413.7 (65.3) 385.3 (33.8) < 0.0005 < 0.0005
QTmin (ms) 354.8 (51.1) 343.6 (30.7) 0.026 0.094
QTpeak (ms) 319.1 (56.2) 301.5 (33.2) 0.001 0.005
Heart rate (bpm) 76.6 (16.9) 74.3 (12.9) 0.202 0.592
QTc (ms) 459.4 (47.6) 425.2 (34.3) < 0.0005 < 0.0005
QTdisp (ms) 58.8 (30.8) 41.7 (21.3) < 0.0005 < 0.0005
TpTe (ms) 94.5 (30.2) 83.8 (22.3) 0.001 0.018
*Univariate ANOVA; †ANOVA analysis adjusted for sex, diabetes mellitus, coronary artery disease, previous stroke and beta-blockers.
Statistically significant (p < 0.05) is shown in bold.
Table 3 Multiple regression analysis of QTmax, QTpeak, and Qtmin in patients with syncope
Regression models Coefficient (B) 95% confidence interval p
QTmax
QTmax (univariate analysis) 28.334 16.166–40.502 < 0.0005
QTmax (multivariate analysis) 31.072 14.668–47.477 < 0.0005
Sex 6.931 19.386–5.525 0.274
Previous stroke 15.165 39.787–9.456 0.226
Coronary artery disease 32.424 17.584–47.263 < 0.0005
Diabetes mellitus 3.669 17.212–9.875 0.594
Beta-blockers 1.470 13.318–16.259 0.845
QTpeak
QTpeak (univariate analysis) 17.661 6.873–28.449 0.001
QTpeak (multivariate analysis) 20.538 6.136–34.939 0.005
Sex 10.727 21.661–0.208 0.054
Previous stroke 12.833 34.449–8.782 0.244
Coronary artery disease 27.794 14.766–40.822 < 0.0005
Diabetes mellitus 1.596 10.294–13.486 0.792
Beta-blockers 10.542 2.442–23.525 0.111
QTmin
QTmin (univariate analysis) 11.189 1.344–21.035 0.026
QTmin (multivariate analysis) 11.550 1.980–25.080 0.094
Sex 7.732 18.005–2.540 0.140
Previous stroke 12.236 32.543–8.072 0.237
Coronary artery disease 17.434 5.194–29.673 0.005
Diabetes mellitus 6.377 17.548–4.793 0.262
Beta-blockers 9.917 2.281–22.115 0.111
Statistically significant (p < 0.05) is shown in bold.
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(18,19), QTdisp is generally longer in the chronic
phase of myocardial infarction (13). It was interest-
ing that, in our study, mean QTmax, mean QTpeak
and mean QTdisp were longer in patients with
syncope than controls, although the control subjects
more frequently had CAD compared with patients
with syncope. A possible reason for this observation
is that the patients with syncope might have more
severe structural non-ischaemic cardiopathy than
controls; these cardiopathies could be myocardial
fibrosis, left ventricular hypertrophy or cardiac auto-
nomic neuropathy (12). So, QT intervals could
depend on severity of underlying structural cardiopa-
thy rather than CAD and, therefore, they could rep-
resent a marker of this severity.
Usually, women have longer QTc (14,20) and
shorter QTdisp (21) and TpTe (22) than men. In
our study, the differences in ventricular repolarisa-
tion measurements between cases and controls seem
not to depend on sex differences between two
groups owing to the fact that on multivariable
logistic regression model, there are no significant
differences between women and men. The marked
sex differences in ventricular repolarisation could
be explained by differences in circulating sex hor-
mones in women and men (14,23). Since the
patients in our study were mostly elderly people,
the differences in sex hormones were less marked
between women and men and, therefore, the ven-
Table 4 Regression analysis of QTc, QTdisp and TpTe in patients with syncope
Regression models Coefficient (B) 95% confidence interval p
QTc
QTc (univariate analysis) 34.134 24.464–43.805 < 0.0005
QTc (multivariate analysis) 27.597 14.156–41.038 < 0.0005
Sex 5.859 16.064–4.347 0.259
Previous stroke 8.821 11.353–28.995 0.390
Coronary artery disease 6.654 5.506–18.813 0.282
Diabetes mellitus 5.089 6.008–16.186 0.367
Beta-blockers 8.771 20.889–3.346 0.155
QTdisp
QTdisp (univariate analysis) 17.145 10.964–23.326 < 0.0005
QTdisp (multivariate analysis) 19.522 11.049–27.995 < 0.0005
Sex 0.802 5.631–7.235 0.806
Previous stroke 2.930 15.647–9.788 0.651
Coronary artery disease 14.990 7.325–22.655 < 0.0005
Diabetes mellitus 2.709 4.287–9.704 0.447
Beta-blockers 8.447 16.085 to 0.808 0.030
TpTe
TpTe (univariate analysis) 10.673 4.497–16.849 0.001
TpTe (multivariate analysis) 10.535 1.841–19.229 0.018
Sex 3.796 2.805–10.397 0.259
Previous stroke 2.332 15.381–10.717 0.725
Coronary artery disease 4.630 3.235–12.495 0.248
Diabetes mellitus 5.265 12.442–1.913 0.150
Beta-blockers 9.071. 16.909 to 1.234 0.023



























Figure 1 Predictive role (sensibility and specificity) of
electrocardiographic indexes (QT max, QT min, QT peak,
QT dispersion, QTc, TpTe) towards syncope diagnosis
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tricular repolarisation measurements did not differ
significantly.
Some studies found QTc and QTdisp significantly
longer in diabetic patients compared with non-dia-
betic patients (24–26). These differences seem to
depend more on the cardiac autonomic neuropathy,
secondary to diabetes mellitus than to diabetes mell-
itus per se (27,28). In our study, the differences in
ventricular repolarisation measurements in diabetic
and non-diabetic patients were not significant.
A study by Seftchick et al. (10) found that previ-
ous stroke is a common predisposing condition for
QTc prolongation. Our study does not confirm this
finding, possibly because the rate of patients with
previous stroke was low.
Some studies found a significant reduction in
QTdisp and TpTe in patients with arterial hyperten-
sion, long-QT syndrome and heart failure taking
beta-blockers (29–31), supporting the theory that
beta-blocker therapy reduces dispersion of repolarisa-
tion and protects patients from the onset of ventricu-
lar arrhythmias. Our study confirmed these findings
showing that beta-blockers were significantly associ-
ated with shorter mean QTdisp and mean TpTe on
multivariable logistic regression (see Table 4).
A study by Aggarwal et al. (17) evaluated the
prognosis of QT interval in emergency department
patients with syncope; they found that a QTc
≥ 500 ms was a predictor of increased mortality
among those patients. In our study, we related QT
intervals of patients with syncope with different
scores according to SFSR, EGSYS and OESIL
scores.
The SFSR (3) is a study that evaluated the onset
of serious outcomes in patients with syncope within
7 days of their emergency department visit; therefore,
it evaluated the short-term prognosis. The presence
of a score ≥ 1 distinguished patients at high risk of
serious outcomes with a sensitivity of 96% and a
specificity of 62%. Our study showed a significantly
longer mean QTc in patients with score 1 and 2 than
the patients with score 0 and a significantly longer
mean QTdisp in patients with score 1 than in those
with score 0. The lack of statistical significance for
higher scores is probably because of the reduced
number of these subgroups. Therefore, in our study
a prolonged QTc and a prolonged QTdisp could be
additional markers of worse short-term prognosis.
Evaluation of Guidelines in SYncope Study is a
validated score used to identify those patients likely
to have a cardiac syncope (4) and to predict the
long-term mortality (follow up of 21–24 months) of
patients with syncope (32). Patients at high risk had
a score ≥ 3. In our study, patients with score 3 had a
longer mean QTc than those with score 0. OESIL is
a risk stratification system used to identify indepen-
dent predictors of total mortality within the first
12 months after the initial evaluation of emergency
department patients with syncope (5). Subjects with
a score of 2 or higher were assumed to be at inter-
mediate or high risk. In our study, patients with
score 2 and 3 had a longer mean QTc than patients
with score 0. The lack of statistical significance for
higher scores in both EGSYS and OESIL scores is
probably because of the reduced number of these
subgroups. Therefore, according to our study it is
possible to affirm that a prolonged QTc could be a
predictive marker of a worse long-term prognosis
and of a diagnosis of cardiac syncope. Because 8.72%
of our patients had a diagnosis of cardiac syncope
and 46.98% had a likely cardiac cause according to
the EGSYS score, it is possible that a high rate of
cardiac syncope was misdiagnosed or undiagnosed in
our study. Therefore, QTc could be proposed to
reduce the diagnostic errors in these patients.
Study limitations
Our study has certain limitations. A larger sample
would certainly increase the statistical power of the
study. The retrospective design may cause missing
data regarding the diagnosis or the aetiology of syn-
cope. Manual measurements of intervals without the
support of any technology that could ensure a more
precise measurement may also be an aspect to be
taken into account.
Conclusions
In conclusion, our study demonstrated that, in a
population of patients admitted to internal medicine
departments, QTc > 424.8 ms (sensibility: 81.88 –
specificity: 57.86), QTdisp > 50 ms (sensibility: 48.99
– specificity: 81.43), QTmax > 410 ms (sensibility:
46.31 – specificity: 83.57), TpTe > 100 ms (sensibil-
ity: 31.54 – specificity: 89.29) and QTpeak > 330 ms
(sensibility: 30.87 – specificity: 82.86) had a predic-
tive value for diagnosis of syncope; therefore, QT
measurements could help the clinician to diagnose
syncope in patients who have an unclear anamnesis.
Furthermore, prolonged QTc and QTdisp were
associated with high risk of serious outcomes at
SFSR and prolonged QTc was associated with inter-
mediate and high risk at EGSYS and OESIL risk
scores; therefore, QTc and QTdisp could be consid-
ered as possible independent markers of syncope
severity beyond the current understanding of their
arrhythmic potential.
Further studies are required to elucidate the valid-
ity of our clinical findings.
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